These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8717379)

  • 1. Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack.
    Bretscher PA; Menon JN; Ogunremi O
    J Biotechnol; 1996 Jan; 44(1-3):1-4. PubMed ID: 8717379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.
    Menon JN; Bretscher PA
    Eur J Immunol; 1996 Jan; 26(1):243-9. PubMed ID: 8566074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for low dose BCG vaccination against tuberculosis.
    Bretscher PA
    Immunobiology; 1994 Oct; 191(4-5):548-54. PubMed ID: 7713569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
    Remer KA; Apetrei C; Schwarz T; Linden C; Moll H
    Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.
    Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA
    J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.
    Bretscher PA
    Immunol Today; 1992 Sep; 13(9):342-5. PubMed ID: 1466750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
    Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
    Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection.
    Wakil AE; Wang ZE; Locksley RM
    Exp Parasitol; 1996 Nov; 84(2):214-22. PubMed ID: 8932771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice.
    Doherty TM; Coffman RL
    Exp Parasitol; 1996 Nov; 84(2):124-35. PubMed ID: 8932762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
    Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.